GoutReMonit GoutNCT06211322
The Remote Monitoring of Gout Feasibility Study
A study testing "Urika", a self-management application for patients with gout in people with Gout, run by Diakonhjemmet Hospital at 1 site in Norway.
Trial summary
In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested. Read more about this study
- Who is it for?
- Ages 19 years and older
- Conditions the study is for
- Gout
- What is being tested?
- "Urika", a self-management application for patients with gout
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 21 participants
- Where
- 1 siteNorway
- Study dates
- 27 Feb 2024to 11 Oct 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or non-pregnant, non-nursing female >18 years of age at screening
- Patients with a clinical diagnosis of gout
- Patients who fulfil the American College of Rheumatology (ACR)/EULAR classification criteria
- Serum urate level >360 μmol/L at inclusion
- Having a smartphone/tablet
Who cannot join
- Contraindication for urate lowering therapy
- Unstable medical conditions (e.g,, uncontrollable hypertension, impaired liver function); known stage 3b or higher chronic kidney disease (estimated glomerular filtration (eGFR) rate/creatinine clearance <45 mL/min); severe infection or gastrointestinal bleed
- Major co-morbidities (e.g., malignancies, severe cardiovascular disease, severe diabetes mellitus, severe respiratory diseases)
- Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The ReMonit Gout Feasibility Study
In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.
Read the detailed description
In this feasibility study various outcome measures will be assessed to determine whether the app (Urika) is viable, practical, and useful. The study will include assessments of technical, operational, clinical, and trial aspects of feasibility.
- Conditions
- Gout
- Being tested
- "Urika", a self-management application for patients with gout
- Medical subject headings
- Gout
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
"Urika", a self-management application for patients with goutDevice
The self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals.
| Study group | Role | What they receive |
|---|---|---|
| To determine the feasibility of a patient self-management application (Urika) in patients with gout. | Experimental | The intended purpose of the app is to support self-management for patients with gout that initiate urate lowering therapy. Receives: Device: "Urika", a self-management application for patients with gout |
What is being measured
The primary outcome is the main question the study is designed to answer.
Desirable feasibility level
Acceptable overall feasibility of the app with ≥70% of the secondary endpoints indicating feasibility.
Measured: Through study completion, an average of 3 months
Secondary outcomes (31)
App performance and functionality
Acceptable number of errors (≤5 errors per participant) in the performance and functionality experienced by the patients and project group members
Measured: Through study completion, an average of 3 months
Patient-reported software usability
Considered feasible if the System Usability Scale median score is ≥68 on a 0-100 scale, 100= best score
Measured: At 3 months
Patient-reported experiences and perceived benefits with the app
Open responses will be collected in semi-structured interview. No scales or instruments will be used
Measured: At 3 months
Patient and health professionals' training requirements
Measured by registering amount of time spent (minutes) on training
Measured: Pre-baseline for health professionals and at baseline for patients
Patient-reported satisfaction with the app
Measured by a numeric rating scale (NRS) 0-10, higher scores mean better outcome. Acceptable feasibility if >=70% of the participants report score >=5, otherwise considered not acceptable feasibility.
Measured: At 3 months
Integration of workflow for health professionals
Measured by registering time spent on screening and enrollment
Measured: At screening and enrollment
Serum urate level
Considered feasible if there is available data on serum urate levels for ≥90% of patients for calculation of mean levels and proportion with low serum urate level
Measured: At 3 months
Patient-reported software functionality
Total number of reported errors related to the software functionality (e.g., downloading, login, registration of medication, reminders, access to videos, medication adherence, registration of blood test results, urate level graph, blood test history, chat, request new prescription). Considered acceptable feasibility if the number of errors are ≤5 per patient in the performance and functionality experienced by the patients and project group members.
Measured: Through study completion, an average of 3 months
Urate lowering therapy dose escalation
Considered feasible if patient-reported data and the medication history in the app monitored in the platform for health personnel is available for ≥90% of patients.
Measured: Through study completion, an average of 3 months
Patient-reported adherence to serum urate lowering therapy
Patient-reported Medication Adherence Report Scale (MARS-5), score range 5-25, higher scores mean better adherence. Considered acceptable feasibility if >=90% of the patients complete the instrument.
Measured: At 3 months
Acute gout flares
Number of acute gout flares
Measured: At 3 months
Side-effects of urate lowering therapy
Number of side-effects registered in the app or by study nurse or study coordinator
Measured: At 3 months
Adverse events
Number of adverse events (incl. serious adverse events) registered by study medical doctor, study nurse or study coordinator
Measured: At 3 months
Patient satisfaction with the follow-up care
Measured by a single item with 5 response categories, ranging from very dissatisfied to very satisfied, higher scores mean higher satisfaction. Considered acceptable feasibility if >=70% of the participants report to be satisfied or very satisfied.
Measured: At 3 months
Knowledge of gout and recommended treatment
Measured by the Gout Knowledge Questionnaire, 0-10, higher scores mean better outcome. Considered acceptable feasibility if there is available total score data for >=90% of the patients.
Measured: At baseline and 3 months
Pain related to gout
Measured by a numeric rating scale (NRS) 0-10, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.
Measured: At 3 months
Health related quality of life
Measured by the Euro Quality of Life 5 Dimensions 5 Levels, each item is scored 1-5, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.
Measured: At 3 months
Activity limitations
Measured by Work Productivity and Activity Impairment (WPAI) item no.6, 0-10, lower scores mean better outcome. Considered acceptable feasibility if there is available data for >=90% of the participants.
Measured: At 3 months
Number of consultations in specialist or primary healthcare
Considered acceptable feasibility if there is available data for ≥90% of patients on patient-reported visits in specialist or primary healthcare
Measured: At 3 months
Costs and time for traveling
Considered acceptable feasibility if there is available data for ≥90% of patients on patient-reported time for travelling to the hospital
Measured: At 3 months
Sick leave and time off work
Considered acceptable feasibility if there is available data for ≥90% of participants using self-report
Measured: At 3 months
Eligible patients per month
Number of eligible patients per month.
Measured: At enrollment
Recruitment rate
Acceptable recruitment rate is ≥50% of eligible patients.
Measured: After enrollment
Patient dropout
Number of patients that withdraw from the study. Acceptable withdrawal rate is ≤20% of included patients.
Measured: At 3 months
Trial logistics
Acceptable overall trial logistics (Identification, screening, recruitment, patient training, data collections, monitoring blood test results, renewal of prescriptions) evaluated as Yes vs. No by the study group.
Measured: At 3 months
Patients' app use: videos watched
Count the number of videos watched per participant. Considered acceptable feasibility if ≥70% of the participants have watched at least 1 video.
Measured: Through study completion, an average of 3 months
Patients' app use: registrations of daily medication adherence
Count the number of registrations of daily medication adherence. Considered acceptable feasibility if ≥70% of the participants have registered at least 1 adherence.
Measured: Through study completion, an average of 3 months
Patients' app use: registration of serum urate levels
Count the number of registered serum urate levels. Considered acceptable feasibility if ≥90% of the patients register their serum urate level monthly.
Measured: Through study completion, an average of 3 months
Patients' app use: chat messages
Count the number of chat messages. Considered acceptable feasibility if ≥70% of the participants register at least 1 chat message.
Measured: Through study completion, an average of 3 months
Patients' app use: flare registering
Count the number of flare registering. Considered acceptable feasibility if ≥10% of the participants register 1 flare.
Measured: Through study completion, an average of 3 months
Potential risk and challenges
Incidence of hinders that could harm a successful clinical evaluation of the app in a large randomised, controlled trial.
Measured: At 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2024
- Study start27 Feb 2024
- Primary completion26 Sep 2024
- Study completion11 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for GoutStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Diakonhjemmet Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Nina Osteras, Diakonhjemmet Hospital
- Investigators
- Nina Østerås, Prof., Principal investigator, Diakonhjemmet Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06211322
- Sponsor's protocol ID
- 23/02662
- Other IDs
- 2023054
- Acronym
- ReMonit Gout
- Status last verified
- Dec 2024
- First submitted
- 20 Dec 2023
- Last updated
- 11 Dec 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Stjarne J, Aanesen F, Sohus S, Abhishek A, Dalbeth N, Hammer HB, Kristianslund EK, Tveter AT, Uhlig T, Berg IJ, Osteras N. A self-management app in a digital treat-to-target gout-care approach: the ReMonit Gout feasibility study. Scand J Rheumatol. 2026 Aug 13:1-13. doi: 10.1080/03009742.2026.2706265. Online ahead of print.
PubMed 42592900
Study at a glance
From the registry record, last updated by the sponsor on 11 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The ReMonit Gout Feasibility Study
- ClinicalTrials.gov ID
- NCT06211322
- Acronym / sponsor ID
- ReMonit Gout / 23/02662
- Conditions
- Gout
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Diakonhjemmet HospitalUniversity, hospital or other
- Study start
- 27 Feb 2024 (actual)
- Primary completion
- 26 Sep 2024 (actual)
- Study completion
- 11 Oct 2024 (actual)
- First posted
- 18 Jan 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
In this feasibility trial, a digital follow-up treatment strategy with patient self-management app (Urika) and remote monitoring in specialist healthcare for patients with gout will be tested.
Detailed description
In this feasibility study various outcome measures will be assessed to determine whether the app (Urika) is viable, practical, and useful. The study will include assessments of technical, operational, clinical, and trial aspects of feasibility.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| To determine the feasibility of a patient self-management application (Urika) in patients with gout. | Experimental | Device: "Urika", a self-management application for patients with goutThe intended purpose of the app is to support self-management for patients with gout that initiate urate lowering therapy. |
Who may qualify
- Ages
- 19 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Male or non-pregnant, non-nursing female >18 years of age at screening
- Patients with a clinical diagnosis of gout
- Patients who fulfil the American College of Rheumatology (ACR)/EULAR classification criteria
- Serum urate level >360 μmol/L at inclusion
- Having a smartphone/tablet
Key exclusion criteria (4 listed)
- Contraindication for urate lowering therapy
- Unstable medical conditions (e.g,, uncontrollable hypertension, impaired liver function); known stage 3b or higher chronic kidney disease (estimated glomerular filtration (eGFR) rate/creatinine clearance <45 mL/min); severe infection or gastrointestinal bleed
- Major co-morbidities (e.g., malignancies, severe cardiovascular disease, severe diabetes mellitus, severe respiratory diseases)
- Psychiatric or mental disorders, alcohol abuse or other substance abuse, language barriers or other factors which makes adherence to the study protocol difficult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| "Urika", a self-management application for patients with goutThe self-management software application (Urika) will include information videos on gout and treatment, reminders of daily medication and blood tests, a built-in algorithm for medical dosage escalation, visualization and log of serum urate levels, motivational gamification, asynchronous chat function patient-health professionals, and a platform for remote monitoring by health professionals. | Device | To determine the feasibility of a patient self-management application (Urika) in patients with gout. |
Primary outcome
Desirable feasibility level
Time frame: Through study completion, an average of 3 months
Acceptable overall feasibility of the app with ≥70% of the secondary endpoints indicating feasibility.
31 secondary outcomes
App performance and functionality
Time frame: Through study completion, an average of 3 months
Patient-reported software usability
Time frame: At 3 months
Patient-reported experiences and perceived benefits with the app
Time frame: At 3 months
Patient and health professionals' training requirements
Time frame: Pre-baseline for health professionals and at baseline for patients
Patient-reported satisfaction with the app
Time frame: At 3 months
Integration of workflow for health professionals
Time frame: At screening and enrollment
Serum urate level
Time frame: At 3 months
Patient-reported software functionality
Time frame: Through study completion, an average of 3 months
Urate lowering therapy dose escalation
Time frame: Through study completion, an average of 3 months
Patient-reported adherence to serum urate lowering therapy
Time frame: At 3 months
Acute gout flares
Time frame: At 3 months
Side-effects of urate lowering therapy
Time frame: At 3 months
Adverse events
Time frame: At 3 months
Patient satisfaction with the follow-up care
Time frame: At 3 months
Knowledge of gout and recommended treatment
Time frame: At baseline and 3 months
Pain related to gout
Time frame: At 3 months
Health related quality of life
Time frame: At 3 months
Activity limitations
Time frame: At 3 months
Number of consultations in specialist or primary healthcare
Time frame: At 3 months
Costs and time for traveling
Time frame: At 3 months
Sick leave and time off work
Time frame: At 3 months
Eligible patients per month
Time frame: At enrollment
Recruitment rate
Time frame: After enrollment
Patient dropout
Time frame: At 3 months
Trial logistics
Time frame: At 3 months
Patients' app use: videos watched
Time frame: Through study completion, an average of 3 months
Patients' app use: registrations of daily medication adherence
Time frame: Through study completion, an average of 3 months
Patients' app use: registration of serum urate levels
Time frame: Through study completion, an average of 3 months
Patients' app use: chat messages
Time frame: Through study completion, an average of 3 months
Patients' app use: flare registering
Time frame: Through study completion, an average of 3 months
Potential risk and challenges
Time frame: At 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 11 Dec 2024.
- Derived from this study: PubMed 42592900Stjarne J, Aanesen F, Sohus S, Abhishek A, Dalbeth N, Hammer HB, Kristianslund EK, Tveter AT, Uhlig T, Berg IJ, Osteras N. A self-management app in a digital treat-to-target gout-care approach: the ReMonit Gout feasibility study. Scand J Rheumatol. 2026 Aug 13:1-13. doi: 10.1080/03009742.2026.2706265. Online ahead of print.
Related trials for Gout
RecruitingPhase 4
Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Participants With Gout
Gout
RecruitingPhase 3
A Study of Dotinurad Versus Allopurinol in Tophaceous Gout
Tophaceous Gout
Not yet recruitingPhase 3
Combined Metabolic Activator Supplementation in Subjects Diagnosed With Gout
Gout Disease
Enrolling by invitation
The Remote Monitoring of Gout Study
Gout Initiating Urate-loweringUrate-lowering Therapy
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Nina Østerås, Prof. principal investigator
Diakonhjemmet Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing "Urika", a self-management application for patients with gout in people with Gout, run by Diakonhjemmet Hospital at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 11 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Desirable feasibility level (time frame: Through study completion, an average of 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06211322, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 Dec 2024.